Guggenheim Capital LLC Buys 26,675 Shares of Zoetis Inc. $ZTS

Key Points

• Guggenheim Capital LLC increased its stake in Zoetis Inc. by 11% during the 1st quarter, acquiring an additional 26,675 shares to total approximately 269,436 shares valued at $44.36 million.
• Research firms have mixed reviews for Zoetis, with Leerink Partners downgrading the stock from "outperform" to "market perform" while Piper Sandler raised its target price from $210 to $215.
• Zoetis reported earnings of $1.76 EPS for the last quarter, exceeding analyst expectations, and has set FY 2025 guidance at 6.300-6.400 EPS.

Guggenheim Capital LLC raised its stake in shares of Zoetis Inc. (NYSE:ZTS - Free Report) by 11.0% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 269,436 shares of the company's stock after acquiring an additional 26,675 shares during the period. Guggenheim Capital LLC owned about 0.06% of Zoetis worth $44,363,000 as of its most recent SEC filing.

Other hedge funds also recently made changes to their positions in the company. Portside Wealth Group LLC raised its stake in shares of Zoetis by 24.7% during the 1st quarter. Portside Wealth Group LLC now owns 33,709 shares of the company's stock worth $5,550,000 after purchasing an additional 6,672 shares during the period. Tandem Investment Advisors Inc. raised its stake in shares of Zoetis by 100.3% during the 1st quarter. Tandem Investment Advisors Inc. now owns 395,626 shares of the company's stock worth $65,140,000 after purchasing an additional 198,089 shares during the period. Flagship Harbor Advisors LLC raised its stake in shares of Zoetis by 31.2% during the 1st quarter. Flagship Harbor Advisors LLC now owns 7,394 shares of the company's stock worth $1,217,000 after purchasing an additional 1,760 shares during the period. Horizon Financial Services LLC bought a new stake in shares of Zoetis during the 1st quarter worth $380,000. Finally, Sage Rhino Capital LLC raised its stake in shares of Zoetis by 117.6% during the 1st quarter. Sage Rhino Capital LLC now owns 7,014 shares of the company's stock worth $1,155,000 after purchasing an additional 3,791 shares during the period. 92.80% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of research firms have recently commented on ZTS. Leerink Partners cut Zoetis from an "outperform" rating to a "market perform" rating and lowered their target price for the stock from $180.00 to $155.00 in a research note on Thursday, July 17th. Piper Sandler lifted their target price on Zoetis from $210.00 to $215.00 and gave the stock an "overweight" rating in a research note on Monday, August 11th. Stifel Nicolaus cut Zoetis from a "buy" rating to a "hold" rating and lowered their price objective for the company from $165.00 to $160.00 in a research note on Wednesday, June 18th. Leerink Partnrs downgraded shares of Zoetis from a "strong-buy" rating to a "hold" rating in a report on Thursday, July 17th. Finally, UBS Group reduced their target price on shares of Zoetis from $189.00 to $170.00 and set a "neutral" rating for the company in a research note on Wednesday, May 7th. Four research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company's stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $202.43.

Insider Buying and Selling

In other news, EVP Roxanne Lagano sold 652 shares of the business's stock in a transaction on Tuesday, June 3rd. The shares were sold at an average price of $170.00, for a total transaction of $110,840.00. Following the completion of the transaction, the executive vice president directly owned 15,129 shares in the company, valued at $2,571,930. The trade was a 4.13% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 0.16% of the stock is currently owned by insiders.

Zoetis Stock Down 0.0%

ZTS stock opened at $155.12 on Wednesday. The stock has a 50-day simple moving average of $153.53 and a two-hundred day simple moving average of $158.28. Zoetis Inc. has a twelve month low of $139.70 and a twelve month high of $200.33. The firm has a market capitalization of $68.75 billion, a PE ratio of 26.70, a PEG ratio of 2.49 and a beta of 0.88. The company has a quick ratio of 1.04, a current ratio of 1.76 and a debt-to-equity ratio of 1.05.

Zoetis (NYSE:ZTS - Get Free Report) last released its quarterly earnings data on Tuesday, August 5th. The company reported $1.76 EPS for the quarter, beating analysts' consensus estimates of $1.62 by $0.14. The company had revenue of $2.46 billion during the quarter, compared to analyst estimates of $2.41 billion. Zoetis had a net margin of 27.83% and a return on equity of 56.90%. Zoetis's revenue was up 4.2% compared to the same quarter last year. During the same period last year, the business earned $1.56 earnings per share. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. On average, equities analysts predict that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.